CVE:IPAImmunoprecise Antibodies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immunoprecise Antibodies Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$1.38 -0.10 (-6.76 %) (As of 07/13/2020 04:00 PM ET) Add Compare Share Today's RangeC$1.36Now: C$1.38▼C$1.6050-Day RangeC$1.17MA: C$1.59▼C$1.9452-Week RangeC$0.45Now: C$1.38▼C$2.06Volume406,607 shsAverage Volume252,372 shsMarket CapitalizationC$96.47 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, and Europe. It also provides human antibody development, hybridoma development, genetic immunization, rabbit monoclonal antibody development, recombinant protein expression and production, cryostorage, hybridoma sequencing, antibody generation, antibody purification, polyclonal development, and peptide production services. The company has a collaboration agreement with TetraGenetics, Inc. The company was founded in 1989 and is based in Victoria, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Immunoprecise Antibodies. Previous Next 1.9 Community Rank Outperform VotesImmunoprecise Antibodies has received 40 “outperform” votes. (Add your “outperform” vote.)Underperform VotesImmunoprecise Antibodies has received 66 “underperform” votes. (Add your “underperform” vote.)Community SentimentImmunoprecise Antibodies has received 62.26% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Immunoprecise Antibodies and other stocks. Vote “Outperform” if you believe IPA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IPA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldImmunoprecise Antibodies does not currently pay a dividend.Dividend GrowthImmunoprecise Antibodies does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunoprecise Antibodies insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immunoprecise Antibodies are expected to grow in the coming year, from C($0.05) to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunoprecise Antibodies is -11.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunoprecise Antibodies is -11.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoprecise Antibodies has a P/B Ratio of 6.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.51 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:IPA Previous Symbol CUSIPN/A CIKN/A Webimmunoprecise.com Phone+1-604-8060626Debt Debt-to-Equity Ratio28.76 Current Ratio1.18 Quick Ratio0.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$12.55 million Price / Sales7.68 Cash FlowC$0.03 per share Price / Cash Flow52.41 Book ValueC$0.21 per share Price / Book6.48Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares69,903,000Market CapC$96.47 million Next Earnings Date8/26/2020 (Estimated) OptionableNot Optionable TSXV:IPA Rates by TradingView Receive IPA News and Ratings via Email Sign-up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Immunoprecise Antibodies (CVE:IPA) Frequently Asked Questions How has Immunoprecise Antibodies' stock been impacted by COVID-19 (Coronavirus)? Immunoprecise Antibodies' stock was trading at C$0.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IPA shares have increased by 89.0% and is now trading at C$1.38. View which stocks have been most impacted by Coronavirus. When is Immunoprecise Antibodies' next earnings date? Immunoprecise Antibodies is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for Immunoprecise Antibodies. Has Immunoprecise Antibodies been receiving favorable news coverage? News stories about IPA stock have trended very negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Immunoprecise Antibodies earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Immunoprecise Antibodies. Who are some of Immunoprecise Antibodies' key competitors? Some companies that are related to Immunoprecise Antibodies include Paradigm Biopharmaceuticals (PAR), SIGA Technologies (SIGA), Biotest (BIO), Neptune Wellness Solutions (NEPT), TELIX Pharmaceutical (TLX), Starpharma (SPL), Silence Therapeutics (SLN), Altimmune (ALT), iShares Diversified Alternatives Trust (ALT), ProMetic Life Sciences (PLI), Pfenex (PFNX), IMV (IMV), Emblem (EMC), Medicenna Therapeutics (MDNA) and Ergomed (ERGO). View all competitors. What other stocks do shareholders of Immunoprecise Antibodies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunoprecise Antibodies investors own include Northwest Pipe (NWPX), ProntoForms (PFM), Algonquin Power & Utilities (AQN), Allstate (ALL), Albemarle (ALB), Altagas (ALA), AGNC Investment (AGNC), Advanced Energy Industries (AEIS), Automatic Data Processing (ADP) and Adaptimmune Therapeutics (ADAP). Who are Immunoprecise Antibodies' key executives? Immunoprecise Antibodies' management team includes the following people: Dr. James S. Kuo M.B.A., M.D., Chairman (Age 54)Dr. Jennifer Bath, Pres, CEO & DirectorMr. Robert Beecroft, Founder & DirectorMr. Charles Wheelock, Global Chief Technology OfficerMs. Lisa Helbling, Chief Financial Officer What is Immunoprecise Antibodies' stock symbol? Immunoprecise Antibodies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IPA." How do I buy shares of Immunoprecise Antibodies? Shares of IPA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Immunoprecise Antibodies' stock price today? One share of IPA stock can currently be purchased for approximately C$1.38. How big of a company is Immunoprecise Antibodies? Immunoprecise Antibodies has a market capitalization of C$96.47 million and generates C$12.55 million in revenue each year. What is Immunoprecise Antibodies' official website? The official website for Immunoprecise Antibodies is immunoprecise.com. How can I contact Immunoprecise Antibodies? Immunoprecise Antibodies' mailing address is 880-580 Hornby St, VANCOUVER, BC V6C 3B6, Canada. The company can be reached via phone at +1-604-8060626. This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
